New Brief: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars

SACRAMENTO, Calif.: SACRAMENTO, Calif., Nov. 4, 2021 /PRNewswire/ -- Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation...

Click to view original post